16Nov
21Sep
RevBio Receives NIH Grant to Explore the Treatment of Vertebral Compression Fractures with Its Regenerative Bone Adhesive Technology
RevBio, Inc., announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute on Aging, part of the National Institutes of Health. This funding will allow the company to pursue the treatment of vertebral compression fractures with its patented bone adhesive technology known as Tetranite®. Because the osteoconductive bone adhesive is injectable, the material may be delivered in a minimally invasive procedure. Read more >>
16Sep
RevBio Receives Approval from the U.K.’s Regulatory Authority to Initiate a Clinical Trial for an Optimized Formulation of its Dental Bone Adhesive Biomaterial
RevBio, Inc., announced that it has received approval from the Medicines and Healthcare products Regulatory Agency in the United Kingdom to start a 15-patient clinical trial to examine the safety and efficacy of immediately stabilized dental implants following tooth extractions using an optimized formulation of Tetranite®, the company’s bone adhesive biomaterial. RevBio has optimized its bone adhesive biomaterial primarily by adjusting the pH of the material as it undergoes its self-setting reaction. In addition, the company has also increased the...
26Oct
RevBio Looked Below the Ocean for a Novel Way to Treat Bone Fractures
With nearly two decades as an engineer in the medical device industry under his belt, Brian Hess, CEO of RevBio and co-inventor of Tetranite bone adhesive technology, has long held a palpable fascination with biomaterials. Read more >>
07Apr
RevBio Receives a $2 Million NIH Grant to Pursue the Treatment of Wrist Fractures with Its Innovative Bone Adhesive Technology
RevBio, Inc., announced that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant expected to total $2 million over two years from the National Institute on Aging, part of the National Institutes of Health. This funding will allow the company to pursue the treatment of wrist fractures with its patented bone adhesive technology known as Tetranite®. Read more >>
10Mar
RevBio Awarded Funding to Conduct an In Vivo Bone Experiment on the International Space Station
RevBio, Inc., announced that it has been awarded the opportunity to conduct an in vivo research experiment on the International Space Station U.S. National Laboratory (ISS National Lab). Read more >>
19Feb
Sealing the Deal – Using Bone Glue to Treat Pain from Wisdom-Tooth Extractions
For many teens, having one or more wisdom teeth removed is a health milestone after the first third molar teeth come in at the very back of the mouth and there isn’t enough room for them. But with this milestone also often comes another one – their first exposure to opioids. “Of about 10 million wisdom-tooth extractions done in a year, about a third come with a prescription for an opioid,” says George Kay, D.M.D., Chief Scientific Officer at the...
05Feb
RevBio Enters the Animal Health Market to Help Improve Canine Dental Care
As its first veterinary application, RevBio, Inc. announced that it has initiated a clinical study to validate the use of its innovative bone adhesive biomaterial to fill tooth extraction sockets in dogs in order to improve healing, maintain and support jaw thickness, and restore the structural stability which may help resist potential mandibular fractures. Read more >>
05Aug
LaunchPad Medical Rebrands as RevBio and Launches an Updated Website
Executives from LaunchPad Medical, Inc. announced that the company has rebranded. Its new name, RevBio, was chosen since it more accurately portrays the objective of developing its revolutionary Tetranite® bone adhesive biomaterial platform. Read more >>
08Jul